NAFTIDROFURYL IN COMPARISON TO ALPROSTADI L IN PERIPHERAL ARTERIAL OCCLUSIVE DISEASE STAGE-III AND STAGE-IV

A prospective, open, randomised study was performed in 30 patients wit h peripheral arterial occlusive disease in stade III and IV comparing either 400 mg Naftidrofuryl or 40 mug Alprostadil i. v. twice daily du ring 21 days. Assessment of treatment success by response of the main symptom (either rest pain or necrosis) resulted in a responder rate of 11 patients in each treatment group. Complete recovery of rest pain a ppeared in 7 of 13 rest pain patients under Naftidrofuryl and 9 of 14 Alprostadil patients. Complete healing of necrosis succeeded in 1 Naft idrofuryl patient. A partial success was found in 6 Naftidrofuryl and 4 Alprostadil patients. Thus a comparison between both active compound s does not show any relevant difference of therapeutical benefit under the defined treatment conditions. No side effects occurred causing wi thdrawal of treatment. A cost-benefit-analysis results in a considerab le advantage in the use of Naftidrofuryl.